[Recommendations for the diagnosis and treatment of Sjögren's syndrome in China]

Zhonghua Nei Ke Za Zhi. 2023 Sep 1;62(9):1059-1067. doi: 10.3760/cma.j.cn112138-20221027-00797.
[Article in Chinese]

Abstract

Sjögren's syndrome (SS) is a chronic systemic autoimmune disease characterized by lymphocyte proliferation and progressive exocrine gland damage. In addition to the impairment of salivary and lacrimal gland function, SS can present with multi-system and multi-organ involvement, accompanied by autoantibodies in serum and hyperimmunoglobulinemia. SS can be divided into primary and secondary forms based on the absence or presence, respectively, of concurrent connective tissue diseases such as systemic lupus erythematosus and rheumatoid arthritis. Based on evidence and guidelines from China and other countries, the Chinese Rheumatology Association drafted standardized criteria for the diagnosis and treatment of primary SS. The objectives were to standardize the detection and interpretation of key indicators for the diagnosis of SS, including serum anti-SSA antibody and labial gland pathology, suggest the use of the widely accepted European League Against Rheumatism (EULAR)-SS disease activity index for the evaluation of the disease, and standardize the rational management of SS patients with topical and systemic therapies.

干燥综合征(SS)是一种以淋巴细胞增殖及进行性外分泌腺体损伤为特征的慢性炎症性自身免疫病。临床除有唾液腺、泪腺功能受损外,亦可出现多系统多脏器受累,血清中存在自身抗体和高免疫球蛋白血症。SS 根据是否伴发其他结缔组织病分为继发性SS和原发性SS(pSS),前者常继发于系统性红斑狼疮、类风湿关节炎等。中华医学会风湿病学分会在借鉴国内外诊治经验和指南的基础上,制订了本规范,旨在规范SS诊断中关键指标(如血清抗SSA抗体和唇腺病理学)的检测和解读,采用公认的疾病活动指标评价疾病,规范局部和系统受累的合理诊治。.

Publication types

  • English Abstract

MeSH terms

  • Arthritis, Rheumatoid*
  • Autoantibodies
  • China
  • Humans
  • Sjogren's Syndrome* / diagnosis
  • Sjogren's Syndrome* / therapy

Substances

  • Autoantibodies